Medpace Holdings, Inc.
NasdaqGS-MEDP
Company Overview
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
Name
Medpace Holdings, Inc.
CEO
Dr. August James Troendle M.D.
Website
www.medpace.com
Sector
Life Sciences Tools and Services
Year Founded
1992
Profile
Market Cap
$11.18B
EV
$10.82B
Shares Out
30.93M
Revenue
$2,030.05M
Employees
5,800
Margins
Gross
66.91%
EBITDA
20.17%
Operating
18.79%
Pre-Tax
19.56%
Net
16.74%
FCF
24.77%
Returns (5Yr Avg)
ROA
14.43%
ROTA
37.93%
ROE
34.99%
ROCE
31.59%
ROIC
14.55%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
$406.91
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
$510.89M
Net Debt
-$357.17M
Debt/Equity
0.2
EBIT/Interest
690.22
Growth (CAGR)
Rev 3Yr
25.45%
Rev 5Yr
20.89%
Rev 10Yr
22.68%
Dil EPS 3Yr
31.9%
Dil EPS 5Yr
35.18%
Dil EPS 10Yr
21.35%
Rev Fwd 2Yr
13.24%
EBITDA Fwd 2Yr
17.42%
EPS Fwd 2Yr
21.18%
EPS LT Growth Est
16.52%
Dividends
Yield
—
Payout
—
DPS
—
DPS Growth 3Yr
—
DPS Growth 5Yr
—
DPS Growth 10Yr
—
DPS Growth Fwd 2Yr
—